Prevalence of Malnutrition in Oncology (PreMiO)
Recruitment status was Recruiting
It is estimated that up to 30% of cancer patients die because of the effects of malnutrition, caused by a discrepancy between nutritional needs and intake (or utilization) of energy and essential nutrients. Malnutrition and its severe complication, cancer cachexia, are negative prognostic factors in neoplastic patients, inducing Decreased response and tolerance to antineoplastic treatments, decline in the functional status, reduced quality of life and reduced survival. Prevalence data on malnutrition in italian oncology patients are lacking and the available literature data on weight loss and malnutrition in oncology refer to patients in different phases of disease and therapy. Most importantly , strategies for prevention of malnutrition and cachexia in oncology are still largely disregarded and scarcely implemented.
The main objective of this project is to assess the prevalence of malnutrition in patients undergoing first medical oncology visit in Italy. Secondary objective is to increase awareness of metabolic and nutritional issues among medical oncologists, thus favoring the inclusion of metabolic-nutritional screening and monitoring in medical oncology protocols. This would in turn contribute to reduce the negative consequences of malnutrition- and cachexia-related complications.
|Study Design:||Observational Model: Ecologic or Community
Time Perspective: Prospective
|Official Title:||The PreMiO Study: The Prevalence of Malnutrition in Oncology.|
- Malnutrition [ Designated as safety issue: No ]Malnutrition will be assessed by Mini Nutritional Assessment, biochemical analysis and diagnostic criteria of pre-cachexia.
- Anorexia [ Designated as safety issue: No ]Anorexia will be assessed via a modified version of AC/S-12 FAACT, via Visual Analogue Scale and specific questionnaire.
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||October 2012 (Final data collection date for primary outcome measure)|
|Cancer patients undergoing first medical oncology visit.|
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01622036
|Contact: Maurizio Muscaritoli, MDfirstname.lastname@example.org|
|Sapienza University of Rome||Recruiting|
|Rome, Italy, 00185|
|Contact: Maurizio Muscaritoli, MS +3906409972016 email@example.com|
|Principal Investigator: Maurizio Muscaritoli, MD|
|Sub-Investigator: Simone Lucia, MD|